Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Terminated 1

Sponsor Class

OTHER 6INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Conditions

Neoplasms 3214Carcinoma, Non-Small-Cell Lung 2727Breast Neoplasms 2550Colorectal Neoplasms 1461Prostatic Neoplasms 1307Neoplasm Metastasis 1300Multiple Myeloma 1112Melanoma 1103Ovarian Neoplasms 1006Lung Neoplasms 944Recurrence 924Leukemia, Myeloid, Acute 879Pancreatic Neoplasms 832Lymphoma, Non-Hodgkin 767Lymphoma 713Stomach Neoplasms 692Carcinoma, Renal Cell 660Carcinoma, Hepatocellular 647Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 550Lymphoma, Follicular 515Head and Neck Neoplasms 490Glioblastoma 472Small Cell Lung Carcinoma 447Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 435Advanced Solid Tumors 432Leukemia 426Uterine Cervical Neoplasms 420Urinary Bladder Neoplasms 405

Interventions

Itraconazole 2roniciclib 1aprutumab ixadotin 1anetumab ravtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Medical Oncology × Clear all
NCT02824042 2020-07-31

Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole

Bayer

Phase 1 Completed
63 enrolled

Medical Oncology

NCT02368951 2017-07-12

Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)

Bayer

Phase 1 Terminated
20 enrolled

Medical Oncology

NCT02457351 2016-05-23

Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study

Bayer

Phase 1 Completed
14 enrolled

Medical Oncology

Data powered by HemOnc (CC BY 4.0) Colophon âš¡